Quick Facts
  • Primary Location:
    Kaiser Permanente Vallejo Medical Center
  • Expertise:
    Hematology
    Clinical Trials
  • Speciality:
    Oncology
  • Gender:
    Female
  • Language:
    English
  • Med School:
    Tufts University School of Medicine

Get to Know Dr. Jennifer M. Suga

Dr. Jennifer Suga is an innovative oncologist utilizing the latest clinical advances in treating patients with lung cancer, breast cancer, colorectal cancer and malignant pleural mesothelioma.

Suga serves as chair of the Kaiser Permanente National Lung Cancer Program and has been principal investigator for oncology clinical trials sponsored by the National Cancer Institute for more than a decade, playing a key role in advancing care to its highest level.

She works closely with thoracic surgeon Dr. Jeffrey Velotta as part of a personalized, multidisciplinary approach to treatment that is often used at Kaiser Permanente.

Kaiser Permanente is known as a leader in cancer prevention, treatment and recovery – a reputation that continues to grow with the team effort Suga is part of every day.

Suga also plays a leadership role in the National Cancer Institute’s Thoracic Malignancy Steering Committee and its Community Oncology Research Program.

She has considerable expertise in identifying genetic aberrations across various tumor types that have allowed oncologists to better personalize treatment for patients. She is certified in both oncology and hematology.

Contact Jennifer M. Suga
By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

Specialties of Dr. Jennifer M. Suga

Dr. Jennifer M. Suga’s Experience and Medical Education

  • Kaiser Permanente Medical Center
  • UC Davis Medical Center (Fellowship)
  • Rhode Island Hospital (Residency)
  • Tufts University School of Medicine (M.D.)

Awards and Certifications

  • American Board of Internal Medicine (Hematology)
  • American Board of Internal Medicine (Medical oncology)
  • National Cancer Institute Thoracic Malignancy Steering Committee (Member)
  • Alliance Respiratory Committee, Southwest Cooperative Group (Member)

Publications of Dr. Jennifer M. Suga

  • Damodaran, S. et al. (2022, February 8). Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Journal of Clinical Oncology.
  • Tomlins, S.A. et al. (2021, August 19). Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precision Oncology.
  • Tutt, A.N.J. et al. (2021, June). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine.
  • Abou-Alfa, G.K. et al. (2019, September 5). Assessment of Treatment With Sorafenib Plus Doxorubicin vs. Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?